Astec Lifesciences (NSE:ASTEC) Ending Cash Position: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTEC Astec Lifesciences Ltd NSE:ASTEC
74 GF Score
Price ₹628.30
GF Value ₹877.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Astec Lifesciences Ending Cash Position?

Astec Lifesciences NSE:ASTEC -4.13% 74 Ending Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ASTEC with a GF Score™ of 74/100 and a GF Value™ of ₹877.18 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Astec Lifesciences's Ending Cash Position for the quarter that ended in Jun. 2026 was ₹0 Mil.

Astec Lifesciences's annual Ending Cash Position increased from Mar. 2024 (₹5 Mil) to Mar. 2025 (₹6 Mil) and increased from Mar. 2025 (₹6 Mil) to Mar. 2026 (₹100 Mil).

Astec Lifesciences Ending Cash Position Related Terms

Astec Lifesciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Astec Lifesciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astec Lifesciences Ending Cash Position Chart

Astec Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.55 4.73 4.72 5.75 100.49

Astec Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ASTEC
74GF Score
Astec Lifesciences Ltd NSE:ASTEC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astec Lifesciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Astec Lifesciences's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=5.754+94.736
=100

Astec Lifesciences's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹0 Mil mean?
Astec Lifesciences (NSE:ASTEC) has a Ending Cash Position of ₹0 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Astec Lifesciences and its competitors.
Is Astec Lifesciences' Ending Cash Position too high?
Astec Lifesciences' current Ending Cash Position is ₹0 Mil. Overall, Astec Lifesciences has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' Ending Cash Position compare to CTVA and CF?
Astec Lifesciences' Ending Cash Position of ₹0 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for an Agriculture company?
A good Ending Cash Position depends on the Agriculture industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Astec Lifesciences and its competitors. Astec Lifesciences's current Ending Cash Position is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (NSE:ASTEC) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹877.18, compared to a current price of ₹628.30 — trading 28.4% below its estimated fair value. The current Ending Cash Position is ₹0 Mil. Astec Lifesciences' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Astec Lifesciences (NSE:ASTEC), the current Ending Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astec Lifesciences (NSE:ASTEC) Overvalued in 2026?

Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued. The current stock price of ₹628.30 is trading 28.4% below its estimated GF Value™ of ₹877.18. GuruFocus considers Astec Lifesciences to be Modestly Undervalued.

Key valuation signals for NSE:ASTEC:

  • Ending Cash Position: ₹0 Mil
  • GF Value™: ₹877.18 vs. price of ₹628.30 (28.4% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astec Lifesciences Business Description

Other Exchanges 533138:India
Address Eastern Express Highway, Godrej One, 3rd Floor, Pirojshanagar, Vikhroli (East), Mumbai, MH, IND, 400 079
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
74GF Score

Get the complete analysis for NSE:ASTEC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹628.30
Price
₹877.18
GF Value